Hot Features
プレミアム
Biogen Inc (1BIIB)
BIT
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease LEQEMBI is the only FDA-approved anti-amyloid...
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Dapirolizumab pegol (DZP) met its...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd...
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference -New testing method highlights link...
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases The collaboration aims to...
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as...
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025 Robin Kramer, Chief Accounting Officer, to Succeed HimCAMBRIDGE, Mass., Oct. 28, 2024 (GLOBE...
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 The detailed study results confirmed interim...
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB...
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 Late breaker oral presentation to feature final results of the Phase 2 IGNAZ study...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -3.4 | -2.44780417567 | 138.9 | 138.9 | 133.3 | 78 | 135.66546392 | DE |
| 4 | -10.1 | -6.93681318681 | 145.6 | 149.4 | 133.3 | 110 | 144.79394398 | DE |
| 12 | -37.6 | -21.721548238 | 173.1 | 173.4 | 133.3 | 59 | 149.53789207 | DE |
| 26 | -58.8 | -30.2624806999 | 194.3 | 201.5 | 133.3 | 51 | 159.76936433 | DE |
| 52 | -94.1 | -40.9843205575 | 229.6 | 229.6 | 133.3 | 42 | 177.41793783 | DE |
| 156 | -80.1 | -37.1521335807 | 215.6 | 244.6 | 133.3 | 39 | 179.41062663 | DE |
| 260 | -80.1 | -37.1521335807 | 215.6 | 244.6 | 133.3 | 39 | 179.41062663 | DE |
jman4956
2分前
capgain
2分前
Z06 MAN
3分前
patrik
4分前
gregcod
6分前
jimr1717
7分前
Teddytropics
8分前
Frankher
9分前
sctts
10分前
ksquared
11分前
CherryTree1
11分前
303auburn
12分前
ksquared
13分前
LVerstee
13分前
Bngo
14分前
tw0122
14分前
CherryTree1
15分前
Golden Cross
16分前
Golden Cross
16分前
tmmi-newbie
16分前
WooptdooU
16分前
Thomas@yahoo
17分前
frrol
20分前
SkeBallLarry
20分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
